Ribo Advances Cardiometabolic Health with New Clinical Trial for siRNA Therapy

Suzhou Ribo Life Science Launches Clinical Trial Application for Novel siRNA Therapy

On October 8, 2026, Suzhou Ribo Life Science Co., Ltd. announced its significant advancement in addressing the global obesity epidemic with the submission of its Phase Ⅰ Clinical Trial Application (CTA) for RBD3133 in the European Union. This clinical study aims to evaluate the safety and efficacy of RBD3133, a cutting-edge small interfering RNA (siRNA) therapy designed to target INHBE (inhibin subunit beta E). As obesity remains a pressing public health crisis affecting over one billion individuals worldwide, innovative therapeutics like RBD3133 could pave the way for new and effective treatments.

Obesity brings with it a host of medical problems: from type 2 diabetes to cardiovascular diseases, the conditions related to excessive weight can severely diminish quality of life and longevity. The market is ripe for novel therapies, as existing treatments often fail to address the underlying causes of metabolic imbalances. "Despite progress in the field, there is a critical need for innovative solutions that treat the root of health issues associated with obesity," stated Dr. Anders Gabrielsen, Ribo's Chief Medical Officer.

The focus of RBD3133 is on the INHBE gene, which encodes the protein activin E, known to play a role in fat distribution and metabolic health. Research involving human genetics showcases that individuals with certain INHBE gene variants exhibit favourable health profiles, including healthier fat distribution and reduced risk of metabolic diseases. These promising insights have cemented INHBE as a promising therapeutic target.

About the Phase Ⅰ Study

The forthcoming Phase Ⅰ study of RBD3133 will be a meticulously designed randomized, placebo-controlled trial. It will help gauge the safety, tolerability, and pharmacokinetics (how the drug is processed in the body) of RBD3133 when administered subcutaneously to participants with overweight or obesity. This crucial stage will act as the initial assessment of the drug’s effect on humans while laying down the groundwork for possible future trials and commercial development.

The initiation of this trial is a beacon of hope within Ribo's cardiometabolic pipeline. RBD3133 is projected to become a cornerstone therapeutic aimed at alleviating weight-related cardiovascular and metabolic issues. As Ribo's inaugural project in the obesity realm, it reflects a strategic focus on the unmet medical needs of vast populations worldwide.

A Closer Look at Ribo Life Science and Ribocure Pharmaceuticals

Suzhou Ribo Life Science Co. Ltd. operates under the stock number 06938.HK and has established itself as a global player in biopharmaceuticals. The company prides itself on its commitment to developing and commercializing siRNA-based treatments, combining advanced technologies to combat significant health concerns.

Ribocure Pharmaceuticals AB, Ribo's overseas subsidiary, enhances this mission, concentrating on the global development of oligonucleotide therapies by fostering clinical trial capacities and innovative drug pipeline ideas. For individuals seeking revolutionary treatment solutions in the realms of cardiovascular and metabolic health, Ribo and Ribocure are dedicated to delivering effective and beneficial therapies.

For more information on Ribo's cutting-edge research and initiatives, please visit www.ribolia.com or www.ribocure.com.

In conclusion, as we stand at the cusp of the next wave of obesity treatments, Ribo's efforts demonstrate a significant leap in developing targeted therapies that could reshape the landscape of food, nutrition, and public health, offering renewed hope to millions struggling with this complex challenge.